Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
Investigators assert clinical trial design features may have contributed to this antibody-drug conjugate's loss of approvals.
Samir Parekh, MD, Appointed Director of the Center of Excellence for Multiple Myeloma at Mount Sinai
Dr. Parekh’s laboratory focuses on developing personalized treatment strategies for patients with multiple myeloma.
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Dr. Shah discusses the significance and limitations of two studies on dietary factors and risk of myeloma and MGUS.
A plant-based diet is significantly associated with a reduced risk of multiple myeloma.
Dr. Richard shares her passion for cellular therapy, how her mother’s leukemia diagnosis shaped her career, and more.
A US population-based study investigated the associations between MGUS and various dietary patterns.
The experts focused on cilta-cel when comparing the three FDA-approved treatments' efficacies, toxicities, and availability.
CAR T-cell therapy had the best OS and PFS, with BCMA-directed therapies also showing high rates of response.
This myeloma awareness month, clinicians are pushing for new treatment options to accelerate the journey towards a cure.
Within the first cycle of daratumumab-based therapy, all patients achieved serum free light chain reduction of 50% or more.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
A study finds shortened overall survival with thrombotic events more severe in arterial thrombosis than venous thrombosis.
This orally available, selective inhibitor of XPO1 is the first agent of its kind to receive commercialization approval.
BCMA–directed CAR Ts were a vital advancement to RRMM treatment. Now, oncologists wonder which agent works best.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
Do IMID-containing quadruplet therapies represent both the present and future of myeloma treatment?
Linvoseltamab continues to be clinically evaluated as monotherapy and in combination therapy for relapsed or refractory MM.
Lenalidomide is indicated to treat myeloma in combination with dexamethasone and transfusion-dependent anemia due to MDS.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.